Form 4: Nascent Biotech CEO Sean Carrick Acquires 239,300 Shares of Common Stock

Nascent Biotech's CEO, Sean Carrick, acquired 239,300 shares of common stock at $0.17 per share on December 29, 2023, as part of his employment contract.

Summary

• On December 29, 2023, Sean Carrick, the President & CEO, Director, and a 10% Owner of Nascent Biotech Inc. (NBIO), acquired 239,300 shares of common stock.
• The shares were acquired at a price of $0.17 per share.
• This transaction increased Carrick's direct ownership to 22,709,007 shares of common stock.
• The acquisition was part of Carrick's employment contract with the company.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of insider trading activity related to an employment contract. The CEO increasing his stake could be seen as mildly positive, but it's not necessarily indicative of significant future performance.

Positives

• The CEO's acquisition of shares could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment due to the CEO increasing his stake in the company.

Key Dates

Keywords

Nascent Biotech, Sean Carrick, stock acquisition, Form 4, beneficial ownership, NBIO, CEO, director, 10% owner